Biosplice is a company that develops therapies using alternative splicing technology to restore health. The company focuses on creating treatments that harness alternative splicing in human DNA to address various medical conditions.

Biosplice

AgelessRx provides anti-aging treatments supported by longevity science. The organization offers various therapies to assist individuals in managing health concerns related to aging.

AgelessRx

Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.  Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing.  Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function.  Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center.

Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions.  

Learn more at https://www.biosplice.com

CDMRP

Polar Light Ventures

Starling Group

Swicorp

Vickers Venture Partners

Cem Ortabaş

Christian Cadeo

aMoon Fund

Sands Capital Ventures

Eventide

Symbiosis Group

Verition Fund Management

Biosplice Therapeutics

We are pleased to announce our collaboration with Novo Nordisk in the field of diabetes research. This pre-clinical partnership aims to develop first-in-class therapies for diabetes by leveraging our leading position in small-molecule DYRK inhibition.
Learn more about this exciting
collaboration in our latest press release: https://lnkd.in/gw_rUHFQ
#Biotech #Pharma #DiabetesResearch #Collaboration #Innovation #Healthcare #DYRKInhibition #Biosplice #NovoNordisk #FirstInClass #PreclinicalResearch

Arthritis Awareness Month

This Arthritis Awareness Month, we reaffirm our commitment to advancing research and developing innovative treatments to improve the lives of individuals living with knee osteoarthritis.

Arthritis presents significant challenges, impacting mobility, comfort, and overall quality of life. Through our dedication to cutting-edge research, we strive to address not only the symptoms but also the underlying causes of knee osteoarthritis.

Join us in raising awareness and supporting the millions affected by arthritis worldwide.


#ArthritisAwarenessMonth #Biosplice

🧠 Did you know? Alzheimer's disease affects more than memory. Here are 3 things you might not know about Alzheimer's:

1) It impacts multiple cognitive functions beyond memory, including language, decision-making, and even personality.

2) Early detection is crucial. Changes in behavior or cognition could be early signs of Alzheimer's, so it's essential to seek medical attention promptly.

3) Research is advancing. From genetic studies to innovative therapies, scientists are making strides in understanding and treating Alzheimer's.

At Biosplice, we're dedicated to contributing to the fight against Alzheimer's through cutting-edge research and development.  

#Alzheimer #Biosplice

🔍 Today, on International Clinical Trials Day, we pause to recognize the profound impact of clinical research on advancing healthcare worldwide. 💡 Clinical trials are the cornerstone of medical innovation, driving progress and improving patient outcomes. At Biosplice, we're proud to contribute to this important work through our commitment to rigorous research and development. 

#ClinicalTrialsDay #Biosplice

📢 News from Biosplice!

📄 EMJ Rheumatology has selected our presentation as one of the highlights of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO IOF-ESCEO) 2024 in London!

https://lnkd.in/gZQ4SiH3

Read the full article for more insights! #WCO2024 #Osteoarthritis #ClinicalTrials #Lorecivivint #MedicalResearch

🧬World DNA Day
Today, we reflect on the profound impact of genetics on healthcare and the countless possibilities it presents for improving patient outcomes. As we commemorate the discovery of the double helix structure, let's reaffirm our commitment to advancing research and leveraging the potential of genetics research to drive innovation in medicine.

#WorldDNADay #BioSplice #Healthcare #Innovation

🔬 Celebrating International Medical Research Day with Biosplice! 🔬

Today, we recognize the vital role of medical research in shaping the future of healthcare. At Biosplice, we're proud to contribute to health outcomes by focusing on innovative solutions for challenging medical conditions.


Join us in celebrating the incredible impact of medical research on International Medical Research Day!

#InternationalMedicalResearchDay #Biosplice

Biosplice to Present at OARSI 2024 Congress in Vienna! 

We will be showcasing our latest research at the upcoming OARSI 2024 Congress in Vienna, Austria, from April 18th to 21st.

Our presentations include:

- Poster Presentation #299: Radiographic and Pain Outcomes from a Phase 3 Extension Study (OA-07) Evaluating the Safety and Efficacy of Repeat Lorecivivint Injections over 3 Years in Subjects with Severe Knee Osteoarthritis"
- Poster Presentation #297: Treatment with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial 


If you're attending OARSI 2024, we invite you to visit our poster presentations and join us in discussions about the latest developments in the field.

#OARSI2024 #Biosplice #Vienna

Exciting news from Biosplice! We're participating in the World Congress of Osteoarthritis (WCO) 2024, taking place from April 11th to 15th in London, UK. 

At this year's conference, we're excited to present our latest research findings:

🔹 Oral Presentation:
"Radiographic and Pain Outcomes from a Phase 3 Extension Study (OA-07) Evaluating the Safety and Efficacy of Repeat Lorecivivint Injections Over 3 Years in Subjects with Severe Knee Osteoarthritis."

🔹 Oral Poster Presentation P674:
"Treatment with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial."

These presentations highlight our ongoing commitment to advancing the treatment landscape for osteoarthritis and working to improve patient outcomes. 

#WCO2024 #Biosplice #London

🌍 Today is World Health Day, and at Biosplice, we're dedicated to advancing health and well-being for all. 

With a clinical pipeline focused on osteoarthritis, oncology, and early-stage programs in neurology and other areas of significant unmet medical need, we're committed to making a positive impact on global health.

Join us in prioritizing health and working towards a healthier future for everyone! 

#WorldHealthDay #Biosplice

Metric
Company Name	Biosplice	AgelessRx
Symbol
MSH ID	COM:BIOSPLICE	COM:AGELESSRX
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Medical Services
Country	US	US
Stage
Employee Count
Website	biosplice.com	agelessrx.com
LinkedIn	biospliceinc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIOS

COM:BIOSPLICE

Biosplice

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue